![]() |
市場調查報告書
商品編碼
1401917
2030 年精準醫療市場預測:按產品類型、藥物類型、給藥途徑、定序技術、技術、應用、最終用戶和地區進行的全球分析Precision Medicine Market Forecasts to 2030 - Global Analysis By Product Type, By Drug Type, Route of Administration, Sequencing Technology, Technology, Application, End User and By Geography |
根據Stratistics MRC預測,2023年全球精準醫療市場規模將達834億美元,預計2030年將達到2023億美元,預測期內複合年成長率為13.5%。
精準醫療考慮基因、環境和生活方式的個體差異,客製化醫療保健,幫助預防和治療疾病。它依靠基因組定序和資料分析等先進技術,根據個人的獨特特徵來制定醫療決策和治療方法。這種方法旨在透過強調個體化和有針對性的干涉措施來最佳化療效、最大限度地減少副作用並改善整體健康結果。
據世界衛生組織稱,到本十年末,癌症發病率預計將上升 50%,癌症發病率將超過 2,000 萬人。
擴大新基因組技術的使用
新興的基因組技術擴大用於透過提供對個體基因組成前所未有的洞察來推進精準醫學。次世代定序、基於 CRISPR 的基因編輯和先進的生物資訊學能夠實現全面分析和識別與疾病相關的遺傳變異。這些豐富的基因組資料有助於準確的診斷、預後和個體化治療策略,以最佳化治療結果。此外,這些技術的可近性和可負擔性的提高將進一步使基因組資訊民主化,並使精準醫學得到更廣泛的應用。
與治療相關的費用增加
客製化治療通常依賴先進技術和專門藥物,費用可能高得令人望而卻步。這種經濟負擔影響了可近性並限制了這些個體化治療的普及。此外,報銷挑戰和覆蓋範圍差異進一步阻礙了患者獲得服務。
對細胞和基因治療的需求不斷增加
對細胞和基因治療日益成長的需求代表著精準醫學的重大機會。這些療法通常根據個人的基因特徵量身定做,是精準醫療個人化方法的個體化代表。生物技術的進步使得能夠開發出在基因層面上解決各種疾病的創新治療方法。隨著精準醫學的進步,對客製化細胞和基因療法的需求將會增加,為研究、開發和市場擴張鋪平道路。
嚴格的監管標準
嚴格的法規可能會延長核准流程並阻礙及時獲得創新療法。合規性需要嚴格的有效性證據,這會增加研發成本,並可能阻止小型企業和新興企業進入市場。此外,多樣化的全球監管環境使區域標準化和核准變得複雜,阻礙了精準治療的無縫實施。
COVID-19大流行加速了技術和調查方法的進步,對精準醫療市場產生了重大影響。這次大流行凸顯了對個體化醫療解決方案的迫切需求,並強調了快速診斷、疫苗開發和治療方法的重要性。此外,它還促進了全球科學界之間的合作,促進了技術創新,並促進了精準醫學原理與感染疾病管理的結合。
預計在預測期內,口服細分市場將是最大的
口腔領域預計將主導精準醫療市場,因為它提供方便且患者友善的標靶治療。這種給藥方法提高了患者的依從性,並允許根據個人的遺傳特徵制定個體化的治療計劃。口服給藥的普及將促進精準醫療的廣泛採用並將其融入日常醫療保健中。此外,口服藥物配方和技術的進步為醫療保健專業人員提供了提供準確有效治療的選擇,從而有助於保持該細分市場的領先地位。
藥物研發領域預計在預測期內複合年成長率最高
由於人工智慧、基因組學和高通量篩檢等技術進步,預計藥物研發領域將在精準醫學市場顯著成長。這些進步將加速標靶識別、檢驗和藥物開發,並簡化客製化治療的創建。精準醫學對個體差異的關注需要強大的藥物管道,從而推動該領域的投資和創新。此外,生物技術、製藥公司和研究機構之間的合作正在培育新的方法,從而能夠發現高度特異性的治療方法,並且該領域預計將持續擴展。
北美地區佔據了最大佔有率,並有望主導市場。該地區擁有先進的醫療基礎設施、強大的研發措施以及慢性病的高盛行率。有利的政府政策、對精準醫療的大量投資以及主要行業參與者的強大影響力奠定了北美的領導地位。此外,完善的法律規範和積極採用創新醫療技術的方法進一步增強了該地區的優勢。
由於醫療保健基礎設施的快速進步和基因組學投資的增加,預計亞太地區精準醫療市場將快速成長。此外,具有不同遺傳背景的快速成長的人口需要量身定做的醫療保健解決方案。此外,意識的提高和支持性法律規範正在推動精準醫療的採用。總而言之,這些動態使該地區成為成長最快的精準醫療市場。
According to Stratistics MRC, the Global Precision Medicine Market is accounted for $83.4 billion in 2023 and is expected to reach $202.3 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Precision Medicine customizes healthcare by considering individual variability in genes, environment and lifestyle for disease prevention and treatment. It relies on advanced technologies, like genomic sequencing and data analytics, to tailor medical decisions and therapies to a person's unique characteristics. This approach aims to optimize effectiveness, minimize side effects, and improve overall health outcomes by emphasizing personalized, targeted interventions.
According to WHO, cancer incidence is projected to rise by 50% to reach more than 20 million by the end of this decade.
Growing utilization of emerging genomic technologies
The escalating use of emerging genomic technologies propels precision medicine by providing unprecedented insights into an individual's genetic makeup. Next-generation sequencing, CRISPR-based gene editing, and advanced bioinformatics enable comprehensive analysis, identifying genetic variations linked to diseases. This wealth of genomic data facilitates precise diagnosis, prognosis, and personalized treatment strategies, optimizing therapeutic outcomes. Additionally, the growing accessibility and affordability of these technologies further democratize genomic information, making precision medicine more widely applicable.
Elevated expenses associated with therapeutic
Tailored treatments, often relying on advanced technologies and specialized medications, can be prohibitively expensive. This financial burden affects accessibility, limiting widespread adoption of these personalized therapies. Additionally, reimbursement challenges and insurance coverage gaps further hinder patient access.
Increasing need for cell and gene therapies
The escalating demand for cell and gene therapies presents a significant opportunity in precision medicine. These therapies, often tailored to individual genetic profiles, exemplify the personalized approach of precision medicine. Advances in biotechnology allow for the development of innovative treatments addressing various diseases at the genetic level. As precision medicine evolves, the growing need for customized cell and gene therapies opens avenues for research, development, and market expansion.
Strict regulatory standards
Stringent regulations may lengthen the approval process, impeding timely access to innovative treatments. Compliance demands rigorous evidence of efficacy, increasing research and development costs, which could deter smaller firms or startups from entering the market. Additionally, diverse global regulatory landscapes create complexities in standardization and approval across regions, hindering the seamless adoption of precision therapies.
The COVID-19 pandemic significantly influenced the precision medicine market by accelerating advancements in technology and research methodologies. It highlighted the critical need for personalized healthcare solutions and underscored the importance of rapid diagnostics, vaccine development, and treatment modalities. Additionally, it spurred collaborations among global scientific communities, fostering innovation and expediting the integration of precision medicine principles into infectious disease management.
The oral segment is expected to be the largest during the forecast period
The oral segment is anticipated to dominate the precision medicine market as it offers convenient and patient-friendly administration of targeted therapies. This mode of delivery enhances patient compliance and allows for personalized treatment plans tailored to individual genetic profiles. The ease of oral medication fosters widespread adoption, facilitating the integration of precision medicine into routine healthcare practices. Additionally, advancements in oral drug formulations and technologies contribute to the segment's leadership, providing healthcare professionals with more options for delivering precise and effective treatments.
The drug discovery segment is expected to have the highest CAGR during the forecast period
The drug discovery segment is estimated to register remarkable growth within the precision medicine market owing to technological strides like AI, genomics, and high-throughput screening. These advancements expedite target identification, validation, and drug development, streamlining the creation of tailored therapies. Precision medicine's focus on individual variations demands a robust pipeline of drugs, propelling investment and innovation in this sector. Additionally, collaborations between biotech, pharmaceutical companies and research institutions foster novel approaches enabling the discovery of highly specific treatments, which positions this segment for sustained expansion.
North America is poised to dominate the market, securing the largest share. The region boasts advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of chronic diseases. Favorable government policies, substantial investments in precision medicine, and a strong presence of key industry players contribute to North America's leadership. Additionally, a well-established regulatory framework and a proactive approach to adopting innovative medical technologies further bolster the region's dominance.
The Asia Pacific region is anticipated to witness exponential growth in the precision medicine market owing to rapid advancements in healthcare infrastructure and expanding investments in genomics. Moreover, a burgeoning population with diverse genetic backgrounds necessitates tailored healthcare solutions. Additionally, growing awareness, coupled with supportive regulatory frameworks, propels the adoption of precision medicine. Altogether, these dynamics fuel the region to experience the highest surge in precision medicine market expansion.
Some of the key players in Precision Medicine Market include Astarte Medical, AstraZeneca PLC, Biocrates Life Sciences, Biogen, Bristol-Myers Squibb, Eagle Genomics, Labcorp, Medtronic PLC, Menarini Silicon Biosystems, Myriad Genetics Inc., NanoString Technologies, Novartis AG, Pfizer Inc., Qiagen NV, Quest Diagnostics, Roche, Tepnel Pharma Services, Teva Pharmaceutical and Thermo Fisher Scientific Inc.
In November 2023, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Royalty Pharma plc, announced a collaboration to further accelerate the clinical research program for Teva's olanzapine LAI (TEV-'749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-'749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile.
In October 2023, Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA). The Aurora EV-ICD system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous ICDs with a lead (thin wire) placed under the breastbone, outside of the heart and veins. The Aurora EV-ICD delivers lifesaving defibrillation, anti-tachycardia pacing (ATP), and back-up (pause-prevention) pacing therapies via a device similar in size, shape, and longevity to traditional, transvenous ICDs.
In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.